Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
Key Points
Sold 420,000 shares, estimated transaction value approximately $18.10 million (based on average first-quarter 2026 pricing)
Position value declined by approximately $21.27 million quarter over quarter
Change represents approximately 2.23% of reported 13F assets under management
Fund holds zero shares post-trade
The position accounted for approximately 2.0% of AUM in the prior quarter
- 10 stocks we like better than Vera Therapeutics ›
On May 14, 2026, Rhenman & Partners Asset Management AB disclosed it sold out its entire stake in Vera Therapeutics (NASDAQ:VERA), unloading 420,000 shares in an estimated $18.10 million trade based on the quarterly average price.
What happened
According to a Securities and Exchange Commission (SEC) filing dated May 14, 2026, Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics during the first quarter. The estimated transaction value was $18.10 million, based on the average share price over the quarter. The quarter-end value of the position declined by $21.27 million, reflecting the combined impact of share sales and market price movements.
What else to know
The fund fully exited its position in Vera Therapeutics, bringing the position’s share of 13F assets under management to zero.
Top holdings after the filing:
- NYSE: BSX: $39.22 million (4.8% of AUM)
- NASDAQ: REGN: $37.16 million (4.6% of AUM)
- NYSE: LLY: $31.01 million (3.8% of AUM)
- NASDAQ: INSM: $26.12 million (3.2% of AUM)
- NYSE: CVS: $24.17 million (3.0% of AUM)
As of May 13, 2026, shares of Vera Therapeutics were trading at $39.15, up 81.4% over the past year and outperforming the S&P 500 by 55 percentage points.
Prior to the sale, the position accounted for 2.0% of the fund’s assets as of the previous quarter, underscoring its historical significance.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close May 13, 2026) | $39.15 |
| Market capitalization | $2.81 billion |
| Net income (TTM) | ($368.95 million) |
| One-year price change | 81.4% |
Company snapshot
- Develops and advances biologic therapies, including atacicept for immunoglobulin A nephropathy and MAU868 for BK virus infections, both in clinical development.
- Operates a clinical-stage biotechnology business model focused on advancing proprietary drug candidates through clinical trials, with future revenue expected from successful commercialization and potential partnerships or licensing.
- Targets patients with serious immunological diseases; primary customers are expected to be healthcare providers, hospitals, and specialty clinics in the United States.
Vera Therapeutics is a biotechnology company specializing in the development of innovative treatments for serious immunological diseases. The company leverages a pipeline of clinical-stage biologics to address unmet medical needs in nephrology and infectious diseases. With a focused strategy on advancing its lead candidates through regulatory milestones, Vera Therapeutics positions itself to capture value in the high-growth immunology therapeutics market.
What this transaction means for investors
Rhenman & Partners Asset Management, an independent investment firm based in Sweden, recently disclosed the sale of its entire position in Vera Therapeutics, valued at approximately $18.1 million, during the first quarter (the three months ending on March 31, 2026). Here are some key takeaways for investors.
First, let’s review how Vera Therapeutics stock has performed. Over the last three years, shares have advanced by 378%, resulting in a compound annual growth rate (CAGR) of approximately 68.4%. That’s far better than the S&P 500, which has recorded a total return of about 87% over the same period, with a CAGR of 23.2%.
Yet, while the stock has delivered significant gains, investors should remember that it still carries risk. Vera Therapeutics is a biotech stock, which means it can experience volatility. In particular, the release of clinical data, along with approvals or setbacks in the drug approval process, can result in significant price swings.
In other words, Vera Therapeutics isn’t a stock for every investor. However, for those investors with an appetite for volatility, it may be wise to take a closer look at this stock.
Should you buy stock in Vera Therapeutics right now?
Before you buy stock in Vera Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vera Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 26, 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Regeneron Pharmaceuticals. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
Recommended Articles
